Indivior Pharmaceuticals vs Lantheus Holdings
Lantheus Holdings is the larger business, with $1.54bn of revenue in fiscal 2025 against $1.24bn for Indivior Pharmaceuticals (1.2 times as much). Indivior Pharmaceuticals grew faster (4.3% against 0.5%). Indivior Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 16.9% against 15.2%.
| Latest fiscal year | Indivior PharmaceuticalsINDV, 2025 | Lantheus HoldingsLNTH, 2025 |
|---|---|---|
| Revenue | $1.24bn | $1.54bn |
| Revenue growth | 4.3% | 0.5% |
| Net income | $210m | $234m |
| Operating margin | 21.1% | 20.2% |
| Net margin | 16.9% | 15.2% |
| Return on equity | — | 21.4% |
| Free cash flow | −$93.0m | $354m |
| Cash | $195m | $359m |
| Total debt | $319m | $569m |
| Debt to equity | — | 52.2% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $11.0m | $300m |
| Employees | 838 | 1,193 |
| Market value | $4.43bn | $6.55bn |
| Price vs our value range | Above our value range | Within our value range |
| Moat score | — | 63 (Moderate) |
| Insider trades, 12 months | 10 buys, 3 sales | 0 buys, 5 sales |